Safety and Pharmacokinetics of 566C80, a Hydroxynaphthoquinone with Anti-Pneumocystis carinii Activity: A Phase I Study in Human Immunodeficiency Virus (HIV)-Infected MenWalter T. Hughes, Mandy Rogers, Wren Kennedy et al.|The Journal of Infectious Diseases|1991Cited by 74
Efficacy and Safety Exposure–Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin LymphomaBrian Hess, Joseph Boni, William Townsend et al.|The AAPS Journal|2021Cited by 13
Sa1935 Population Pharmacokinetic Modeling Analysis of Golimumab in Adult Patients With Moderately to Severely Active Ulcerative ColitisOmoniyi J. Adedokun, William J. Sandborn, Zhenhua Xu et al.|Gastroenterology|2016Cited by 7
Mo1215 Serum Golimumab Exposure and the Incidence of Selected Safety Events in Patients With Ulcerative Colitis Following Treatment With Golimumab: An Exploratory Analysis of the PURSUIT Study DataOmoniyi J. Adedokun, William J. Sandborn, Zhenhua Xu et al.|Gastroenterology|2014Cited by 3
Abstract 1367: Relationship between exposure and safety/efficacy of loncastuximab tesirine (Lonca) in B-cell non-Hodgkin lymphoma (B-NHL)Brian Hess, Joseph Boni, Weiyun Z. Ai et al.|Cancer Research|2021Cited by 0